|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
These results clearly demonstrate OCT1-independent cellular sorafenib uptake indicating that OCT1 is apparently not a valid biomarker of sorafenib response in HCC.
|
31350763 |
2020 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Expression of Oct1 was measured in rodent HCC models (spontaneously generated in Fxr<sup>-/-</sup> mice and chemically-induced in rats). hOCT1 was overexpressed in human hepatoma cells (HuH7 and HepG2).
|
30592786 |
2019 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
In the current review, we summarized the reports about OCT1 and HCC in order to present a comprehensive overview of the relationship between OCT1 and HCC.
|
31413596 |
2019 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
The organic cation transporter 1 (OCT1) plays a major role in sorafenib uptake and decreased expression in HCC has been associated with poorer response.
|
28178663 |
2017 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
This study indicates a promising role for intratumoral OCT1 mRNA expression as a prognostic biomarker in therapeutic algorithms in HCC.
|
26872727 |
2016 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
Down-regulation of SLC22A1 encoding the organic cation transporter-1 (OCT1) may affect the response of hepatocellular carcinoma (HCC) and cholangiocarcinoma (CGC) to sorafenib, a cationic drug.
|
23532667 |
2013 |
|
Liver carcinoma
|
0.380 |
AlteredExpression
|
disease |
BEFREE |
Real time PCR showed a downregulation of SLC22A1 and SLC22A3 in HCC compared to TST (p ≤ 0.001).
|
22439694 |
2012 |
|
Liver carcinoma
|
0.380 |
Biomarker
|
disease |
BEFREE |
In this report, we show that Oct-1 acts as an activator of catalase, by binding to the catalase promoter in hepatocellular carcinoma (HCC) cell lines.
|
21985966 |
2011 |
|
Obesity
|
0.320 |
Biomarker
|
disease |
BEFREE |
Effects of SLC22A1 Polymorphisms on Metformin-Induced Reductions in Adiposity and Metformin Pharmacokinetics in Obese Children With Insulin Resistance.
|
27407018 |
2017 |
|
Obesity
|
0.320 |
Biomarker
|
disease |
CTD_human |
In both fat depots, OCT1 gene expression and protein levels were significantly increased in obese subjects.
|
20956498 |
2011 |
|
Obesity
|
0.320 |
Biomarker
|
disease |
BEFREE |
Although the effect of obesity on drug disposition remains an important issue for clinicians, little is known about the effects of obesity on organic cation transporter 1 (OCT1) expression and activity.
|
20814161 |
2010 |
|
Malignant tumor of colon
|
0.310 |
GeneticVariation
|
disease |
BEFREE |
In contrast, loss of one or both Oct1 alleles progressively increased tumor burden in a colon cancer model driven by loss-of-heterozygosity of the tumor suppressor gene Apc.
|
31059499 |
2019 |
|
Malignant tumor of colon
|
0.310 |
Biomarker
|
disease |
CTD_human |
Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
|
15059925 |
2004 |
|
Colonic Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Global gene expression analysis of rat colon cancers induced by a food-borne carcinogen, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine.
|
15059925 |
2004 |
|
Acute kidney injury
|
0.200 |
Therapeutic
|
disease |
RGD |
Regulation of renal organic anion and cation transporters by thymoquinone in cisplatin induced kidney injury.
|
22414646 |
2012 |
|
Cholestasis, Extrahepatic
|
0.200 |
Biomarker
|
disease |
RGD |
Elevated systemic elimination of cimetidine in rats with acute biliary obstruction: the role of renal organic cation transporter OCT2.
|
20814153 |
2010 |
|
Intrahepatic Cholestasis
|
0.200 |
Biomarker
|
disease |
RGD |
Reduced antidiabetic effect of metformin and down-regulation of hepatic Oct1 in rats with ethynylestradiol-induced cholestasis.
|
19002567 |
2009 |
|
Endotoxemia
|
0.200 |
Therapeutic
|
phenotype |
RGD |
Nitric oxide down-regulates the expression of organic cation transporters (OCT) 1 and 2 in rat kidney during endotoxemia.
|
18313662 |
2008 |
|
Asthma
|
0.200 |
Biomarker
|
disease |
RGD |
Down-regulation of the non-neuronal acetylcholine synthesis and release machinery in acute allergic airway inflammation of rat and mouse.
|
17328924 |
2007 |
|
Diabetes Mellitus, Experimental
|
0.200 |
Biomarker
|
disease |
RGD |
Reduced expression of organic cation transporters rOCT1 and rOCT2 in experimental diabetes.
|
14718608 |
2004 |
|
Leukemia, Myelocytic, Acute
|
0.120 |
Biomarker
|
disease |
BEFREE |
These findings elucidate a novel and important role for Oct1 in AML.
|
31295506 |
2019 |
|
Chronic Kidney Diseases
|
0.120 |
GeneticVariation
|
group |
BEFREE |
We induced chronic kidney disease (CKD) with adenine in WT mice, mice with osteocyte-specific deletion of Cyp27b1, encoding the 25-hydroxyvitamin D 1(OH)ase [Oct-1(OH)ase-/-], and mice with global deletion of Cyp27b1 [global-1α(OH)ase-/-]; we then compared extraskeletal calcification.
|
31292298 |
2019 |
|
Chronic Kidney Diseases
|
0.120 |
GeneticVariation
|
group |
GWASCAT |
Genome-Wide Association Studies of Metabolites in Patients with CKD Identify Multiple Loci and Illuminate Tubular Transport Mechanisms.
|
29545352 |
2018 |
|
Leukemia, Myelocytic, Acute
|
0.120 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |